According to the Zhitong Finance App, Touyun Biotech (01332.HK) announced its 2026 interim results, with gross profit of HK$9.116 million, a year-on-year decrease of 32.71%; profit attributable to company owners was about HK$198 million, an increase of about 16.6 times over the previous year; profit per share was 7.05 HK cents.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.